799698--4/2/2007--CYTRX

related topics

{product, candidate, development}

{investment, property, distribution}

{competitive, industry, competition}

{property, intellectual, protect}

{product, liability, claim}

{acquisition, growth, future}

{stock, price, share}

{stock, price, operating}

{operation, natural, condition}

{control, financial, internal}

{provision, law, control}

Our Current Financial Resources May Be Diminished If We Elect To Provide RXi with Initial Financing We Will Be Reliant Upon Third Parties for the Development and Eventual Marketing of Our Products We Will Incur Substantial Expenses and May Be Required to Pay Substantial Milestone Payments Relating to Our Product Development Efforts If Our Products Are Not Successfully Developed and Approved by the FDA, We May Be Forced to Reduce or Curtail Our Operations Our Molecular Chaperone Co-Induction Drug Candidates May Not Receive Regulatory Marketing Approvals We Have Identified Material Weaknesses in our Internal Control over Financial Reporting We Are Subject to Intense Competition, and There is No Assurance that We Can Compete Successfully We Will Rely upon Third Parties for the Manufacture of Our Clinical Product Supplies We May Be Unable to Protect Our Intellectual Property Rights, Which Could Adversely Affect the Value of Our Assets We Are Subject to Potential Liabilities From Clinical Testing and Future Product Liability Claims We May Be Unable to Acquire Products Approved For Marketing Risks Associated With Our Ownership of RXi RXi Will Be Subject to Risks of a New Business The Approach RXi is Taking to Discover and Develop Novel Therapeutics Using RNAi is Unproven and May Never Lead to Marketable Products RXi May Be Unable to Protect Its Intellectual Property Rights Licensed From UMMS or May Need to License Additional Intellectual Property from Others. RXi May Not Be Able to Obtain Sufficient Financing We Will Be Required To Dispose of Some of Our RXi Shares, and May Not Be Able To Do So On Attractive Terms RXi Will Retain Discretion Over Its Use of Any Funds That We Provide To It We Will Not Control RXi, And The Officers, Directors and Other RXi Stockholders May Have Interests That Are Different From Ours Products Developed by RXi Could Eventually Compete With Our Products For ALS, Type 2 Diabetes and Obesity and Other Disease Indications RXi Will Be Subject to Competition, and It May Not Be Able To Compete Successfully Risks Associated with Our Common Stock Our Anti-Takeover Provisions May Make It More Difficult to Change Our Management or May Discourage Others From Acquiring Us and Thereby Adversely Affect Stockholder Value Our Outstanding Options and Warrants and the Registrations of Our Shares Issued in and Our Private Financings May Adversely Affect the Trading Price of Our Common Stock

Full 10-K form ▸

799698--4/2/2007--CYTRX_CORP